While shares of Livongo continue to struggle as we predicted deals in the digital diabetes space would go on. Just this morning we learned that Bayer is investing in … wait for it … OneDrop. Per the press release;
“One Drop, a leader in the development of digital therapeutic solutions for diabetes and other chronic conditions, today announced $40 million in Series B financing, led by Bayer, one of the largest pharmaceutical companies in the world. Bayer has also entered a commercial licensing agreement to use One Drop’s platform in Bayer’s global bio-digital efforts in therapeutic areas such as . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.